Hydronidone API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Hydronidone API 851518-71-3?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Hydronidone. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Hydronidone
- Synonyms:
- N-(4-Hydroxyphenyl)-5-methyl-2-pyridone
- Cas Number:
- 851518-71-3
- DrugBank number:
- DB06299
- Unique Ingredient Identifier:
- RXQ128313W
General Description:
Hydronidone, identified by CAS number 851518-71-3, is a notable compound with significant therapeutic applications. Hydronidone has antifibrotic activity.
Indications:
This drug is primarily indicated for: Investigated for use/treatment in liver disease. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Classification:
Hydronidone belongs to the class of organic compounds known as pyridinones. These are compounds containing a pyridine ring, which bears a ketone, classified under the direct parent group Pyridinones. This compound is a part of the Organic compounds, falling under the Organoheterocyclic compounds superclass, and categorized within the Pyridines and derivatives class, specifically within the Hydropyridines subclass.
Categories:
Hydronidone is categorized under the following therapeutic classes: Pyridines. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Hydronidone is a type of Antifibrotic agents
Antifibrotic agents belong to the pharmaceutical API category that focuses on treating fibrosis, a condition characterized by the excessive accumulation of fibrous connective tissue in organs. These agents target the underlying mechanisms involved in fibrosis and help prevent or slow down the progression of the disease.
One commonly used antifibrotic agent is Pirfenidone, which has shown efficacy in treating idiopathic pulmonary fibrosis (IPF). It works by inhibiting the production of pro-inflammatory and fibrotic factors, such as transforming growth factor-beta (TGF-β), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF). By reducing the levels of these factors, Pirfenidone helps suppress the proliferation and activation of fibroblasts, which are responsible for excessive collagen deposition in fibrotic tissues.
Another antifibrotic agent, Nintedanib, also targets IPF. It is a tyrosine kinase inhibitor that blocks the activity of various growth factor receptors, including PDGF, fibroblast growth factor receptor (FGFR), and vascular endothelial growth factor receptor (VEGFR). By inhibiting these receptors, Nintedanib disrupts the signaling pathways involved in fibrosis, thereby reducing fibroblast activation and collagen production.
These antifibrotic agents have shown promising results in clinical trials and have been approved for the treatment of IPF in several countries. They represent a significant advancement in the management of fibrotic diseases and offer hope to patients by slowing down disease progression and improving overall outcomes.
In conclusion, antifibrotic agents are a vital category of pharmaceutical APIs that target the underlying mechanisms of fibrosis. Through their action on key molecular pathways involved in fibrotic tissue deposition, these agents help reduce the accumulation of fibrous connective tissue and provide potential therapeutic benefits for patients with fibrotic diseases.
